NYSE: MSMorgan Stanley Stock
$218.38+0.74 (+0.34%)
Updated Aug 13, 2026
MS Price
$218.38
Fair Value Price
N/A
Market Cap
$342.98B
52 Week Low
$141.03
52 Week High
$232.23
P/E
17.46x
P/B
2.95x
P/S
4.16x
PEG
3.01x
Dividend Yield
1.9%
Revenue
$78.04B
Earnings
$20.16B
Gross Margin
100%
Operating Margin
33.23%
Profit Margin
25%
Debt to Equity
13.39
Operating Cash Flow
-$16B
Beta
1.17
Next Earnings
Oct 14, 2026
Ex-Dividend
N/A
Next Dividend
Aug 14, 2026
MS Overview
Morgan Stanley provides financial products and services to corporations, governments, financial institutions, and individuals. It has three business segments: Institutional Securities, Wealth Management, and Investment Management. Morgan Stanley was founded in 1924 and is headquartered in New York, NY.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine MS's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +5.11% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Capital Market
Industry Rating
F
MS
Ranked#22 of 65
Ranked#22 of 65
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $10.94 | A | |
| $49.62 | B | |
| $115.18 | B |
Be the first to know about important MS news, forecast changes, insider trades & much more!
MS News
Overview
Due Diligence Score
–
Industry Average (29)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how MS scored across 38 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
MS ($218.38) is trading above its intrinsic value of $86.18, according to an updated version of Benjamin Graham's Formula from Chapter 11 of "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
MS is poor value based on its earnings relative to its share price (17.46x), compared to the US market average (14.17x)
P/E vs Market Valuation
MS is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
There are 35 more MS due diligence checks available for Premium users.
Valuation
MS price to earnings (PE)
For valuing profitable companies with steady earnings
Company
17.46x
Industry
19.56x
Market
14.17x
MS is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
MS is poor value based... subscribe to Premium to read more.
P/E vs Market Valuation
MS price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
2.95x
Industry
3.09x
MS is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
MS price to earnings growth (PEG)
For valuing profitable companies with growth potential
MS is poor value relative... subscribe to Premium to read more.
PEG Value Valuation
MS's financial health
Profit margin
Revenue
$21.3B
Net Income
$5.6B
Profit Margin
25.5%
MS's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$1.7T
Liabilities
$1.6T
Debt to equity
13.39
MS's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
MS's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$2.7B
Investing
-$7.2B
Financing
$37.1B
MS vs Capital Market Stocks
Morgan Stanley Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.